TGFB1 and neoplasm: Liu et al.’s study suggests that there are two different configurations of smad3, psmad3C and psmad3L, and the actions of the TGF-β signaling pathway with different configurations of smad3 may produce different tumor outcomes and prognoses [38, 39].